Researchers have been excited about this new drug, a groundbreaking dual agonist showing promising results in initial trials for size reduction . It works by targeting both pathways : GLP-1 and GIP, these, when engaged , support regulate hunger and boost energy expenditure . Initial findings suggest considerable body management and possible improve